Reading Room Production — page 483

From: "Kurilla, Michael (NIH/NIAID) [E]" < @niaid.nih.gov> To: "Fauci, Anthony (NIH/NIAID) [E]" < @niaid.nih.gov> Subject: Fw: Heads up Date: Sat, 10 Apr 2010 20:29:29 -0400 Importance: Normal Tony, I'll add on on slide with 4 bullets summarizing the WH activity. Mike -------------------------- Sent from my BlackBerry Wireless Handheld. Please excuse my typing; I suffer from blackberry thumb syndrome. From: Collins, Francis (NIH/OD) [E] To: Fauci, Anthony (NIH/NIAID) [E] Cc: Hudson, Kathy (NIH/OD) [E]; Kurilla, Michael (NIH/NIAID) [E]; Heilman, Carole (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E]; Wood, Gretchen (NIH/OD) [E]; Flowers, Susan (NIH/OD) [E] Sent: Sat Apr 10 17:15:09 2010 Subject: RE: Heads up Hi Tony, Thanks for this heads up. I would very much like to hear more about how this MCM initiative is shaping up. Perhaps Friday morning April 16 would work, but I am ccing Gretchen and Sus to encourage them to find the right time. Francis From: Fauci, Anthony (NIH/NIAID) [E] Sent: Saturday, April 10, 2010 11:27 AM To: Collins, Francis (NIH/OD) [E] Cc: Hudson, Kathy (NIH/OD) [E]; Kurilla, Michael (NIH/NIAID) [E]; Heilman, Carole (NIH/NIAID) [E]; Conrad, Patricia (NIH/NIAID) [E]; Folkers, Greg (NIH/NIAID) [E]; Auchincloss, Hugh (NIH/NIAID) [E]; McGowan, John J. (NIH/NIAID) [E] Subject: Heads up Francis: First, I hope that things have improved greatly with your daughter's illness. Second, I want to give you a heads up that I have called your office to arrange for me to brief you on how things have been progressing with our weekly White House meetings with Heidi Avery of the National Security Staff (NSS). As you may know she is John Brennan's Deputy and is intensively interested in "transforming" how we respond to deliberate and naturally occurring biological threats through the development of medical countermeasures (MCM). She has been making a number of proposals that have been discussed at length at these meetings and have undergone a continual series of modifications based on comments from the participants. The "Program" has now matured to the point of including 4 elements: 1) boosting regulatory science; 2) developing Transformational Centers of Excellence for Advanced Development and Manufacturing of MCM; 3) establishing an independent strategic investment firm (i.e. a government venture capital-like organization) for innovation in MCM; 4) and finally an idea that she got from what NIAID has been doing for some time on a relatively small scale - the development of a "concept exploitation focus" to help stimulate discovery and translation. What we have been doing is playing an active role from the time a grantee makes a discovery, but has no experience in pushing it into translation. NIAID has served as a "sherpa" or chaperone for the investigators by providing them with NIAID assets (reagents, animal models, connection to the regulatory process, etc.) to begin the process of translation. This is totally compatible with your interest in translational research on a broader scale including the CTSAs , particularly in light of the Cures